Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ)
CNY 13.93
(-0.5%)
CNY 13.93
(-0.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.75 Billion CNY | 1.22% |
| 2022 | 8.65 Billion CNY | 12.87% |
| 2021 | 7.66 Billion CNY | 116.04% |
| 2020 | 3.54 Billion CNY | 5.38% |
| 2019 | 3.36 Billion CNY | 1.82% |
| 2018 | 3.3 Billion CNY | -4.24% |
| 2017 | 3.45 Billion CNY | -1.78% |
| 2016 | 3.51 Billion CNY | 83.72% |
| 2015 | 1.91 Billion CNY | 122.81% |
| 2014 | 858.71 Million CNY | -16.04% |
| 2013 | 1.02 Billion CNY | 43.32% |
| 2012 | 713.59 Million CNY | 5.01% |
| 2011 | 679.51 Million CNY | 11.9% |
| 2010 | 607.25 Million CNY | 43.69% |
| 2009 | 422.62 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 9.41 Billion CNY | 7.5% |
| 2024 Q3 | 9.26 Billion CNY | -2.77% |
| 2024 Q2 | 9.52 Billion CNY | 1.18% |
| 2023 Q3 | 8.32 Billion CNY | 3.27% |
| 2023 Q4 | 8.75 Billion CNY | 5.16% |
| 2023 Q1 | 8.64 Billion CNY | -0.08% |
| 2023 FY | 8.75 Billion CNY | 1.22% |
| 2023 Q2 | 8.06 Billion CNY | -6.72% |
| 2022 Q1 | 7.65 Billion CNY | -0.16% |
| 2022 FY | 8.65 Billion CNY | 12.87% |
| 2022 Q4 | 8.65 Billion CNY | 9.9% |
| 2022 Q3 | 7.87 Billion CNY | 5.82% |
| 2022 Q2 | 7.43 Billion CNY | -2.78% |
| 2021 Q4 | 7.66 Billion CNY | 10.44% |
| 2021 Q3 | 6.94 Billion CNY | 14.17% |
| 2021 FY | 7.66 Billion CNY | 116.04% |
| 2021 Q1 | 5.96 Billion CNY | 68.16% |
| 2021 Q2 | 6.07 Billion CNY | 1.9% |
| 2020 Q3 | 3.89 Billion CNY | 0.54% |
| 2020 FY | 3.54 Billion CNY | 5.38% |
| 2020 Q1 | 3.59 Billion CNY | 6.75% |
| 2020 Q2 | 3.87 Billion CNY | 7.88% |
| 2020 Q4 | 3.54 Billion CNY | -8.98% |
| 2019 Q4 | 3.36 Billion CNY | -9.03% |
| 2019 FY | 3.36 Billion CNY | 1.82% |
| 2019 Q1 | 3.18 Billion CNY | -3.57% |
| 2019 Q2 | 3.29 Billion CNY | 3.46% |
| 2019 Q3 | 3.7 Billion CNY | 12.21% |
| 2018 FY | 3.3 Billion CNY | -4.24% |
| 2018 Q4 | 3.3 Billion CNY | 9.11% |
| 2018 Q3 | 3.03 Billion CNY | -3.77% |
| 2018 Q2 | 3.14 Billion CNY | -6.0% |
| 2018 Q1 | 3.34 Billion CNY | -2.97% |
| 2017 Q1 | 3.06 Billion CNY | -12.67% |
| 2017 Q4 | 3.45 Billion CNY | 1.98% |
| 2017 Q3 | 3.38 Billion CNY | 13.33% |
| 2017 Q2 | 2.98 Billion CNY | -2.68% |
| 2017 FY | 3.45 Billion CNY | -1.78% |
| 2016 Q3 | 2.34 Billion CNY | 8.27% |
| 2016 FY | 3.51 Billion CNY | 83.72% |
| 2016 Q4 | 3.51 Billion CNY | 49.77% |
| 2016 Q1 | 2.12 Billion CNY | 11.25% |
| 2016 Q2 | 2.16 Billion CNY | 1.85% |
| 2015 Q2 | 1.63 Billion CNY | 40.81% |
| 2015 FY | 1.91 Billion CNY | 122.81% |
| 2015 Q4 | 1.91 Billion CNY | 1.98% |
| 2015 Q3 | 1.87 Billion CNY | 14.84% |
| 2015 Q1 | 1.16 Billion CNY | 35.1% |
| 2014 Q1 | 1.09 Billion CNY | 7.02% |
| 2014 Q2 | 1.08 Billion CNY | -0.47% |
| 2014 Q3 | 897.24 Million CNY | -17.63% |
| 2014 Q4 | 858.71 Million CNY | -4.29% |
| 2014 FY | 858.71 Million CNY | -16.04% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q4 | 1.02 Billion CNY | 0.0% |
| 2013 FY | 1.02 Billion CNY | 43.32% |
| 2012 FY | 713.59 Million CNY | 5.01% |
| 2011 FY | 679.51 Million CNY | 11.9% |
| 2010 FY | 607.25 Million CNY | 43.69% |
| 2009 FY | 422.62 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Cachet Pharmaceutical Co., Ltd. | 11.02 Billion CNY | 20.602% |
| ZJAMP Group Co., Ltd. | 12.99 Billion CNY | 32.605% |
| Luyan Pharma Co.,Ltd. | 8.81 Billion CNY | 0.676% |
| Ji Yao Holding Group Co., Ltd. | 2.72 Billion CNY | -221.84% |